10-Q: Sanara MedTech Reports Q2 2026 Results, Merger with MiMedx Announced

Sanara MedTech Inc. (SMTI) filed its Form 10-Q for the quarter ended June 30, 2026, reporting increased net revenue and Adjusted EBITDA, alongside the significant announcement of a merger agreement with MiMedx Group, Inc.

Summary

• Sanara MedTech Inc. reported its Form 10-Q for the quarter ended June 30, 2026, detailing financial performance and strategic updates.
• Net revenue increased by 9% to $28.1 million for the three months ended June 30, 2026, compared to $25.8 million in the prior year period.
• For the six months ended June 30, 2026, net revenue grew 14% to $55.9 million.
• Adjusted EBITDA for the three months ended June 30, 2026, was $5.0 million, up from $4.7 million in the prior year.
• For the six months ended June 30, 2026, Adjusted EBITDA was $9.3 million, up from $7.4 million in the prior year.
• The company announced a definitive agreement to merge with MiMedx Group, Inc., with the transaction expected to close by year-end, subject to shareholder and regulatory approvals.
• The THP segment was discontinued and presented as discontinued operations, with its results excluded from continuing operations for all periods presented.
• Cash and cash equivalents stood at $15.4 million as of June 30, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously optimistic, with significant progress in revenue growth and strategic realignments, but overshadowed by a pending merger and ongoing operational costs.

Positives

• Net revenue increased by 9% to $28.1 million for the three months ended June 30, 2026, and by 14% to $55.9 million for the six months ended June 30, 2026, driven by strong performance in soft tissue repair products.
• Adjusted EBITDA showed a positive trend, increasing to $5.0 million for the three months and $9.3 million for the six months ended June 30, 2026, indicating improved operational profitability.
• The company has a strong gross margin, approximately 93% for the three and six months ended June 30, 2026, reflecting efficient cost management of goods sold.
• The company announced a significant merger agreement with MiMedx Group, Inc., offering $33.00 in cash and 0.4735 shares of MiMedx common stock per share of Sanara MedTech common stock, providing a clear exit strategy for shareholders.
• The company's core surgical products, CellerateRX Surgical and BIASURGE, continue to show strong sales growth, supported by increased market penetration and distribution network expansion.

Negatives

• The company reported a net loss from continuing operations of $0.4 million for the three months ended June 30, 2026, compared to a net income of $0.5 million in the prior year period.
• For the six months ended June 30, 2026, the net loss from continuing operations was $13,457, compared to a net loss of $0.1 million in the prior year period.
• Selling, general, and administrative (SG&A) expenses increased significantly, by $3.0 million for the three months and $5.7 million for the six months ended June 30, 2026, largely due to increased sales and marketing expenses and legal/advisory services for strategic initiatives.
• Interest expense and share of losses from equity method investments contributed to higher 'Other expense', impacting net income.
• The company's cash and cash equivalents decreased to $15.4 million from $16.6 million at the end of the previous year, although management believes current liquidity is sufficient for the next 12 months.

Risks

• The merger with MiMedx may not be consummated due to various closing conditions, which could lead to significant unrecouped expenses and negative market reactions.
• The announcement and pendency of the merger may adversely affect the company's business, relationships with suppliers, agents, distributors, consultants, and employees, and limit its ability to pursue other attractive business opportunities.
• The company's future business and financial results could be negatively affected if the merger is delayed or does not occur, potentially resulting in liability for termination fees and negative market reactions.
• The company is subject to intense competition in its markets, and failure to compete effectively could impact its business.
• The company's ability to develop and commercialize new products and maintain clinical acceptance and adoption of existing products is critical.
• The company's dependence on licensed technologies and products from third parties presents a risk.
• The company faces risks related to the failure of third-party assessments to demonstrate desired outcomes and the protection of intellectual property rights.

Future Outlook

The company anticipates its current cash and cash equivalents, combined with expected cash flows from operations, will be sufficient to fund its growth strategy and meet anticipated operating expenses and capital expenditures for at least the next 12 months. Future cash needs are expected for product portfolio development, clinical studies, debt repayment, and general corporate purposes. The merger with MiMedx is expected to close by year-end, subject to approvals.

Management Comments

• Management believes that its cash and cash equivalents, when combined with expected cash flows from operations, will be sufficient to fund its growth strategy and to meet its anticipated operating expenses and capital expenditures for at least the next 12 months.
• Management believes Adjusted EBITDA is useful to investors because it facilitates comparisons of core business operations across periods on a consistent basis.
• Management believes that the company operates as a single reportable segment, consistent with the nature of its operations and the financial information regularly reviewed by the Company's CODM.

Industry Context

StockSavvy.ai notes that Sanara MedTech operates in the competitive surgical market, focusing on soft tissue repair and bone fusion products. The company's strategic shift away from the value-based wound care program (THP) and towards its core surgical offerings aligns with industry trends emphasizing specialized, high-margin medical devices. The pending merger with MiMedx, another player in the regenerative medicine and advanced wound care space, suggests potential industry consolidation and a move towards larger entities with broader product portfolios.

Comparison to Industry Standards

• Sanara MedTech's gross margin of approximately 93% is exceptionally high, exceeding typical industry benchmarks for medical device manufacturers, which often range from 50-70%. This suggests strong pricing power or highly efficient cost of goods sold.
• The company's net loss from continuing operations, despite revenue growth, indicates that operating expenses, particularly SG&A and interest expenses, are significant relative to revenue, a common challenge for growth-stage medical technology companies.
• The company's reliance on a single reportable segment (Sanara Surgical) after discontinuing THP is a strategic focus, aiming for operational efficiency and market specialization, which is a common strategy for companies seeking to streamline operations and enhance profitability.

Legal Proceedings

• To the knowledge of the company, there are no material pending legal proceedings.

Related Party Transactions

• The company has a license agreement with Rochal Industries, LLC, a related party, for antimicrobial products. Royalties are paid based on net sales.
• The company has a consulting agreement with Ann Beal Salamone, a director and significant shareholder of Rochal, for patent-related services.
• The company terminated a Transaction Advisory Services Agreement with Catalyst, a related party, effective June 2, 2026.

Stakeholder Impact

• Shareholders: The announced merger with MiMedx offers shareholders $33.00 in cash and 0.4735 shares of MiMedx common stock per share, providing a potential exit and value realization.
• Employees: The pending merger may create uncertainty regarding future roles and operations, potentially impacting morale and retention.
• Suppliers/Distributors: The company's strategy to expand its independent distribution network is ongoing, and the merger could lead to changes in these relationships.
• Creditors: The company's debt covenants, including liquidity and minimum revenue requirements, are being met, and the merger may impact future debt structures.

Next Steps

• Complete the merger with MiMedx Group, Inc., subject to shareholder and regulatory approvals.
• Continue to expand market penetration and develop the independent distribution network for surgical products.
• Advance the product pipeline and focus on enhancing existing product offerings.
• Manage operational expenses, particularly SG&A, to improve profitability.
• Continue to monitor and manage cash flow and liquidity.

Key Dates

Recommendation

The company shows positive revenue and Adjusted EBITDA growth in its core surgical business, which is encouraging. However, the significant increase in SG&A, ongoing net losses from continuing operations, and the substantial uncertainties surrounding the pending merger with MiMedx (including potential termination fees and integration risks) warrant a cautious approach. The merger terms offer a clear cash and stock component, but the ultimate value realization depends on the successful completion and integration of the transaction. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the merger's outcome and post-merger performance.

Keywords

Sanara MedTech, Form 10-Q, Quarterly Report, Medical Technology, Surgical Products, Soft Tissue Repair, Bone Fusion, Merger Agreement